| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Mayo Clinic researchers were highlighted in a recently published video to discuss how the molecular makeup of brain tumors can be used to identify five categories of gliomas, each with different clinical features and outcomes.
“We need to use molecular genetic tools to help improve the classification of gliomas to determine the patient’s prognosis and the specific therapy that the patient should receive,” says Robert Jenkins, M.D., Ph.D., Consultant in the Division of Laboratory Genetics and Genomics at Mayo Clinic.
By determining the classification of glioma, as noted in the video, Mayo Clinic physicians are able to provide the most appropriate treatment to each unique patient case and reduce unnecessary long-term effects of treatment.
View the video, “Unlocking the Power of Gene Expression: Molecular Classification of Brain Tumors.”
About Dr. Robert Jenkins
Dr. Jenkin’s research is focused on cancer genetics, particularly elucidation of the genetic events important for cancer initiation and progression. His primary interest is in the genetics of gliomas, where both his basic genetic studies and clinical translation activities have had a major impact on neuro-oncology.
Dr. Jenkins is a Consultant in the Division of Laboratory Genetics and Genomics. He holds the rank of Professor of Laboratory Medicine and Pathology from the Mayo Clinic College of Medicine and Science with a joint appointment in Clinical Genomics and Biochemistry.
One of Dr. Jenkins’ earliest lifetime goals was to direct both a clinical laboratory and a research laboratory. Thus, he is focused on developing new diagnostic and predictive tests for use in for various cancers.
